Metabolic & Weight Management
GLP-3 RRetatrutide
Triple GIP/GLP-1/glucagon receptor agonist studied in human clinical trials for metabolic and weight research.
Appetite and metabolic-rate researchCardiometabolic marker studiesBody-composition research
How it works in the body
Brain
Stomach
Pancreas
Liver
Muscle
Adipose Tissue
RESEARCH USE ONLYINVESTIGATIONAL COMPOUNDAvailable following assessmentREGENEXA ASSESSMENT
Vial concentration
GLP-3 R
Retatrutide · 5 mgThis is a clinician-reviewed research peptide. Pricing is provided as part of an approved, personalized plan after your assessment is reviewed.
Not sure where to start?
Discover what may fit your goals — a short, personalized Regenexa Assessment.
Take Your Assessment →- 🔒 Secure & encrypted checkout
- 📦 Fast, discreet worldwide shipping
- 🧪 Pharmaceutical-grade quality
- 🔬 Research use only
Not sure where to start? Discover what may fit your goals — a short, personalized Regenexa Assessment.Take Your Assessment →
Long-acting unimolecular tri-agonist; glucagon-receptor activity is the key differentiator from dual GIP/GLP-1 agonists, adding energy-expenditure and hepatic-lipid effects on top of appetite suppression.
Receptors
GIP receptorGLP-1 receptorGlucagon receptor
Half-life: Approximately 6 days, supporting once-weekly research dosing.
Ask Regenexa AI about Retatrutide
Get plain-language answers on mechanism, evidence and how it compares to other peptides — grounded in Regenexa's verified data.
“Is Retatrutide approved for use?”Ask Regenexa AI →Available following assessmentTake Assessment
Cagrilintide
CagriSema
Survodutide
Mazdutide